Arsenic trioxide: An emerging therapy for multiple myeloma

Oncologist

Volumn 6, Issue SUPPL. 2, 2001, Pages 17-21

  Munshi, Nikhil C ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Antiangiogenesis; Apoptosis; Arsenic trioxide; Multiple myeloma

Indexed keywords

ARSENIC TRIOXIDE; PARAPROTEIN;

ANGIOGENESIS; APOPTOSIS; CANCER INHIBITION; CELL PROLIFERATION; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME DELETION 13; CONFERENCE PAPER; CYTOPENIA; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; INFUSION; LUNG TOXICITY; MULTIPLE MYELOMA; PRIORITY JOURNAL;

EID: 0035030143     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.6-suppl_2-17     Document Type: Conference Paper

References (24)

1. Multiple myeloma, macroglobulinemia, and the monoclonal gammopathies
2. Multiple myeloma
3. The biology of multiple myeloma
4. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: An overview of published trials
5. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
6. Standard therapy versus autologous transplantation in multiple myeloma
7. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma
8. Long-term follow-up after high-dose therapy for high-risk multiple myeloma
9. Results of high-dose therapy for 1000 patients with multiple myeloma: Durable complete remissions and superior survival in the absence of chromosome 13 abnormalities
10. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial
11. Novel approaches in myeloma therapy
12. Prognostic factors in multiple myeloma
13. New insights into role of microenvironment in multiple myeloma
14. Angiogenesis in newly diagnosed multiple myeloma: Poor prognosis with increased microvessel density (MVD) in bone marrow biopsies
15. Graft-versus-myeloma effect: Proof of principle
16. Antitumor activity of thalidomide in refractory multiple myeloma
17. Anti-tumour activity of bisphosphonates in human myeloma cells
18. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARα independent manner
19. 2 family members
20. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients
21. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis
22. Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism
23. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis
24. 3) in high risk refractory multiple myeloma